NEWARK,
Calif., June 1, 2022 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company")
today announced that Dinesh V. Patel, Ph.D., President, and
Chief Executive Officer, will present at the Jefferies Healthcare
Conference in New York on
Wednesday, June 8 at 9:30 a.m. ET.
A webcast of the event will be available for 90 days on the
Investors section of the Protagonist Therapeutics website
at http://investors.protagonist-inc.com/.
About Protagonist
Protagonist Therapeutics is a biopharmaceutical company with
peptide-based new chemical entities rusfertide, PN-943, and PN-235
in different stages of clinical development, all derived from the
Company's proprietary technology platform.
Rusfertide is an investigational, injectable hepcidin mimetic
currently in multiple clinical studies for polycythemia vera (PV)
including VERIFY, a single, global Phase 3 randomized,
placebo-controlled trial evaluating the efficacy and safety of a
once weekly, subcutaneously self-administered dose of rusfertide
for patients living with PV, the REVIVE Phase 2 proof-of-concept
clinical trial for polycythemia vera (PV), and the PACIFIC Phase 2
study in PV subjects with high hematocrit levels. A Phase 2a
clinical proof-of-concept study was also recently completed with
rusfertide for patients with hereditary hemochromatosis.
The 12-week induction phase of the IDEAL Phase 2 study of PN-943
in moderate-to-severe ulcerative colitis concluded in April 2022. Although this Phase 2 study missed
its pre-specified primary endpoint of clinical remission at the
450-milligram twice-daily dose, the results support advancement of
the lower 150-milligram twice-daily dose of PN-943 into a Phase 3
study. Efforts to secure a partner to support the financing and
execution of the registrational clinical development program for
PN-943 are underway.
Protagonist has granted Janssen an exclusive worldwide license
to research, develop and commercialize oral IL-23 receptor
antagonists based on the Company's intellectual property. Current
development efforts are centered on PN-235, discovered by
Protagonist and further developed in collaboration with Janssen.
FRONTIER 1, a Phase 2b multicenter,
randomized, placebo controlled, dose-ranging study to evaluate the
safety and efficacy of PN-235 for the treatment of
moderate-to-severe plaque psoriasis, commenced in early 2022.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/protagonist-therapeutics-to-participate-at-the-jefferies-healthcare-conference-301559105.html
SOURCE Protagonist Therapeutics, Inc.